logo
Photographer's warning after encounter with rarely seen Australian animal

Photographer's warning after encounter with rarely seen Australian animal

Yahoo15-07-2025
Under a cloud of mist, vigorous ripples appear on the surface of the water. The animal lingering underneath the surface is one few Australians have seen in the wild – a platypus.
For over a decade, Neil Andison has been photographing them at a creek in Maleny, a quiet town inland from Queensland's bustling Sunshine Coast. 'It started with a surprise sighting and that was it, I was hooked. It was like what some might call a platypus epiphany,' he said.
Andison films platypuses almost every day. He has seen up to 11 in a single sitting, and feels lucky that they're flourishing near his home. But looking more widely across their native range along the east coast of Australia, their numbers are declining. In Victoria, the species is listed as vulnerable to extinction, and in NSW it's near threatened.
The biggest threat to the survival of the platypus is humans, who destroy crucial habitat, pollute creeks, build dams, and contribute to climate change, which makes droughts and bushfires more frequent and severe.
Related: Photographer captures 'incredibly rare' moment between platypus and snake
Because platypus populations are sparse, they are vulnerable to localised extinction. That's why in Victoria, NSW, ACT, South Australia and Tasmania, state governments have restricted the use of Opera House nets, a type of yabbie trap known to frequently kill platypus.
Platypuses need to breathe air to survive. They regularly dive down for one to two minutes, and can survive for up to 11 minutes under water by slowing down their heart rate.
But there's no escape from an Opera House net, because they're fully enclosed and don't provide a route for escape. Platypuses often drown inside the same net after swimming inside in search of a feed of yabbies.
Before the ban in Victoria, the bodies of five platypuses were found dead inside two of the traps at Labertruche Creek, east of Melbourne. And Australia's national science agency, the CSIRO, collected evidence of close to 30 dying in nets in the five years leading to the ban.
While Andison is thankful there is a healthy population of platypus in Maleny, he worries about their future. That's because, despite years of lobbying from conservation groups, Queensland continues to permit their use in waterways where platypuses live.
'I've sent emails to 99 politicians about the problem, and only received automated responses,' Andison said.
'I just don't think they've got the balls to ban them. And it frustrates the living hell out of me.'
Woman with 'specific skills' sets up 280 cameras in search rare animal
Mass bird poisoning fears at suburban shopping centre
Zoo defends $180 experience after video 'stunt' sparks concern
In 2024, Fisheries Queensland released a discussion paper to explore phasing out the use of Opera House nets. It then prepared a consultation report based on the stakeholder feedback, which it said in January would be considered by the government in "due course". No regulatory changes to the use of the nets have been made.
Love Australia's weird and wonderful environment? 🐊🦘😳 Get our new newsletter showcasing the week's best stories.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Shark-like prehistoric whale with razor-sharp teeth discovered off Australia
Shark-like prehistoric whale with razor-sharp teeth discovered off Australia

Yahoo

time37 minutes ago

  • Yahoo

Shark-like prehistoric whale with razor-sharp teeth discovered off Australia

Fossils unearthed along Victoria's Surf Coast have led to the discovery of an ancient whale species with special adaptations for hunting, including large eyes and sharp teeth, shedding light on early marine mammal evolution. The species has been named Janjucetus dullardi after Victoria local resident Ross Dullard, who found the ancient whale's fossil fragments in 2019. Janjucetus dullardi is one of their earliest cousins of modern whales and roamed the seas around 26 million years ago, say researchers from Museums Victoria Research Institute. Unlike the modern gentle giants, Janjucetus dullardi was a fast, sharp-toothed predator with a compact body about the size of a dolphin built for hunting, according to a new study published in the journal Zoological Journal of the Linnean Society. 'It's essentially a little whale with big eyes and a mouth full of sharp, slicing teeth ... Imagine the shark-like version of a baleen whale – small and deceptively cute, but definitely not harmless,' said Ruairidh Duncan, lead author of the study, The prehistoric whale had a short snout, large forward-facing eyes about the size of tennis balls and sharp slicing teeth, researchers say. The early whale ancestor would have been a compact, yet fearsome sight in the warm, shallow seas of ancient Victoria, scientists noted. The findings offer insight into the early evolution of baleen whales – the filter-feeding giant mammals cruising through modern oceans. It also sheds more light on the prehistoric region, now in modern-day Australia, which scientists say was 'once a cradle' for some of the most unusual whales in history. Researchers made the new species discovery based on a partial skull fossil with attached ear bone found in June 2019 by Victoria resident Mr Dullard while walking along the beach. After recognising its scientific importance, the Victoria resident donated the fossil to Museums Victoria, where researchers carefully studied it in detail. 'This kind of public discovery and its reporting to the museum is discovery has unlocked an entire chapter of whale evolution we've never seen before. It's a reminder that world-changing fossils can be found in your own backyard,' said study co-author Erich Fitzgerald, senior curator at Museums Victoria Research Institute. Scientists found that the fragments belonged to a juvenile specimen just over two metres long. They concluded that it belonged to a group of early whales known as mammalodontids that lived around 30 to 23 million years ago. The latest find marks the third known mammalodontid species from Victoria, and only the fourth found worldwide. It is also the first of its kind to preserve teeth and inner ear structures in detail, revealing how early whales fed, heard, moved and behaved in the water. Using advanced CT scans of the ear bones, researchers hope to further understand how the early species sensed its environment for hunting and navigating the oceans. 'This fossil opens a window into how ancient whales grew and changed, and how evolution shaped their bodies as they adapted to life in the sea,' Dr Fitzgerald said. 'We're entering a new phase of discovery. This region is rewriting the story of how whales came to rule the oceans, with some surprising plot twists!' he added,

Researchers stunned by behavior of captive-bred frogs after releasing them into wild: 'Brings us a huge amount of hope'
Researchers stunned by behavior of captive-bred frogs after releasing them into wild: 'Brings us a huge amount of hope'

Yahoo

time7 hours ago

  • Yahoo

Researchers stunned by behavior of captive-bred frogs after releasing them into wild: 'Brings us a huge amount of hope'

In the mountains of Victoria, a success story is unfolding, and it's bringing hope to scientists and communities alike. After the devastating 2019-2020 bushfires, which destroyed much of their habitat, spotted tree frogs have seen their population decline. But now, scientists say that hundreds of captive-bred spotted tree frogs are not only surviving in the wild but also actively exploring their new home. These vivid, 6-centimeter-long frogs were once on the brink. Between invasive predators, extreme weather events, and a deadly fungal disease, the outlook was grim. But thanks to a conservation breeding program by Zoos Victoria, more than 600 frogs and tadpoles have now been released into the Kiewa River. "Quite a large proportion of those animals are actually surviving," said Wild Research Director Matt West, who is leading a team tracking the animals' progress, to The Guardian. "[It] brings us a huge amount of hope that we might be able to recover this population of spotted tree frogs." That hope comes not only from survival rates (more than half of the released frogs have been located again) but also from the fact that many have already hopped up to a kilometer from the release site, meaning they are comfortably settling into their new terrain. Researchers and volunteers put a lot of time into locating the frogs for a head count because they blend seamlessly into the granite boulders and ferns they call home. But the well-earned results suggest a promising return for a species that plays a vital role in local ecosystems by controlling insects and supporting biodiversity. This inspiring story adds to other recent wins in conservation, such as the comeback story of white storks in the United Kingdom and trail camera sightings of the rare quokka in Australia. Each success shows us that ecological healing is possible, especially when communities and scientists work together. And the work continues. The frogs' survival will be monitored long term, but for now, scientists are cautiously optimistic. "Fingers crossed things start looking up for them," said Zoos Victoria biologist Deon Gilbert. Do you think America does a good job of protecting its natural beauty? Definitely Only in some areas No way I'm not sure Click your choice to see results and speak your mind. Join our free newsletter for good news and useful tips, and don't miss this cool list of easy ways to help yourself while helping the planet.

CSL announces rise in full year net profit
CSL announces rise in full year net profit

Yahoo

time9 hours ago

  • Yahoo

CSL announces rise in full year net profit

Major strategic initiatives, including demerger, to transform CSL MELBOURNE, Aug. 18, 2025 /PRNewswire/ -- Global biotherapeutics leader CSL today announced a reported net profit after tax of US$3.0 billion for the 12 months ended 30 June 2025, up 17% on a constant currency basis. Underlying profit (NPATA) was US$3.3 billion, up 14% on a constant currency basis. Dr. Paul McKenzie, CSL's Chief Executive Officer and Managing Director said, "I am pleased to report another on-target result for the 2025 financial year, led by CSL Behring and continued strong demand for our life-saving plasma therapies. "CSL Seqirus continued to show the resilience of its differentiated portfolio and platforms by generating growth in a challenging environment. CSL Vifor grew strongly, underpinned by our resilient iron business and pleasing momentum across the nephrology portfolio," Dr. McKenzie said. Today, the company announced a suite of strategic transformation initiatives designed to ensure continued growth and resilience in a complex operating environment. "Our business has grown this year despite an unprecedented level of challenge and volatility in our external operating environment. Today we are announcing transformational initiatives to reshape and simplify the business, enhance clinical and commercial execution and provide a platform for CSL to focus on our core strengths," Dr. McKenzie said. "These changes are designed to focus our organisation on three Ps: Pipeline, Productivity and People. They will make us match-fit and instil a lean and efficient mindset, reduce complexity and simplify our operating model." A summary of these initiatives is outlined below: Driving Growth, Simplification and Shareholder Returns Research &Development OperatingModel PlasmaNetwork CSL remains steadfast in its commitment to innovation and will drive specific changes that increase the speed of translational research into the clinical setting, while continuing to offer life cycle management expansion to our portfolio. CSL will reduce the proportion of fixed cost in overall spend, and implement initiatives to increase pipeline productivity, including consolidation of R&D footprint. The savings will be directed towards priority programs and developing new disease targets from both internal and external sources. To enhance clinical and commercial execution, a distinctive new Portfolio Development and Commercialisation (PD&C) operating model will integrate R&D, Business Development, and Commercial teams. CSL Behring and CSL Vifor will also combine medical and commercial functions, delivering further synergies and additional revenue growth opportunities. Corporate functions will be streamlined to align to the new operating model. The demand profile for CSL products requires continued growth in the supply of plasma proteins. The successful rollout of Rika and iNomi have driven expected efficiencies, as have manufacturing process improvements, creating opportunities to optimise CSL's plasma collection network. In August 2025 we closed 22 underperforming centres, representing 7% of CSL Plasma's US footprint. The initiatives will result in a net headcount reduction of up to 15% of CSL's employee base. One-off restructuring costs are expected to be approximately $700-$770 million (pre-tax) and $560-$620 million (post-tax), all to be recognised in Financial Year 2026. The cash flow impact is expected to be $400-$450 million in Financial Year 2026, with a further $100 million expected in Financial Year 2027. The initiatives are expected to drive annualised cost savings of $500-550 million progressively over the next three years, with the majority achieved by the end of Financial Year 2027. CSL will look to balance the reinvestment of these savings in high priority opportunities, with the need to deliver sustainable, profitable growth. Intention to demerge CSL Seqirus to shareholders, creating an ASX-listed global vaccine leader CSL today announces its intention for CSL Seqirus to be demerged as a substantial ASX-listed entity before the end of Financial Year 2026. CSL Seqirus is a global leader in seasonal influenza vaccines, with a highly differentiated and market leading product portfolio centred around innovations in cell and adjuvant technologies. A demerger will allow autonomy to set an independent strategic direction, including capitalising on potential opportunities that may arise in a highly dynamic vaccines market, as well as reducing complexity, making the business more agile and efficient to manage. The company will be chaired by Mr Gordon Naylor, an experienced company director and former President of CSL Seqirus. The remaining CSL group will continue to have leading market positions in multiple rare and serious diseases. These franchises have a long track record of delivering value to shareholders, and their scalable platforms will continue to benefit from the positive long-term outlook and demand for their therapies. Both entities will have a sustainable capital structure and access to funding to pursue separate but distinct growth strategies. The demerger will be subject to third party consents, regulatory approvals and CSL will conduct a voluntary shareholder vote. Capital management CSL will recommence a share buyback program. This will be a multi-year, on-market share buyback, starting with A$750m in Financial Year 2026, and is expected to progressively increase over the medium-term. The program will enhance capital efficiency and improve shareholder returns. Joy Linton, CSL's Chief Financial Officer said, "CSL is focused on an efficient and disciplined capital management strategy and is committed to maintaining a strong balance sheet. CSL's net debt / EBITDA ratio has continued to decline and is now below two times which provides opportunities to invest in high returning growth initiatives and external partnerships, while also returning additional cash to shareholders." The buyback will be in addition to the final dividend of US$1.62 per share. The timing and value of shares purchased will be dependent on the prevailing market conditions, share price, opportunities to deploy capital, and other factors. Driving growth, simplification and shareholder returns Commenting on the strategic updates, Dr. McKenzie said, "We firmly believe that a simplified and focused CSL is best for patients, best for our people, and best for our shareholders. The changes announced today will deliver enduring patient value and durable shareholder returns." Dr. Brian McNamee AO, Chair of CSL said, "The Board and Management team are unified in our confidence in the outlook for CSL. We also recognise the need to simplify our structure and remain agile in order to capture this growth. The significant initiatives Paul and his team have outlined today will provide CSL with a renewed focus that will improve shareholder returns. This demerger of CSL Seqirus to our shareholders will create an ASX-listed, global influenza vaccine leader. The company has a great future that will be driven by its strong competitive position in an improving market." Further detail will be provided at CSL's Capital Markets Day on 4 to 6 November 2025 in the United States. Financial Year 2026 Outlook Commenting on CSL's outlook, Dr. McKenzie said: "Financial Year 2026 group revenue growth is anticipated to be approximately 4-5% over Financial Year 2025 at constant currency. "In CSL Behring, we anticipate continued robust demand for our core therapies, as well as the uptake of newer products such as ANDEMBRY® and HEMGENIX®. With the roll-out of the RIKA and iNomi platforms now complete, gross margin is expected to continue to improve. "In Financial Year 2026, CSL Seqirus expects seasonal influenza revenue to stabilise, driven by improving performance in key US segments and launches in other major geographies. We anticipate a substantially lower contribution from avian influenza and COVID-19 than in the prior Financial Year. "CSL Vifor is well positioned to maintain market leading positions, despite new entrants into the iron market. The nephrology franchise will continue to benefit from the ongoing success of therapies such as TAVNEOS® and FILSPARI®. "CSL's NPATA for FY26, excluding the non-recurring restructuring cost, is anticipated to be in the range of approximately $3.45 billion to $3.55 billion at constant currency, representing growth over FY25 of approximately 7-10%. "This guidance assumes no impact from pharmaceutical sector tariffs. It is our current expectation that any such policy would not impact our ability to deliver on the strategic initiatives outlined today. CSL has significant operations in the US and the majority of our commercial portfolio is domestically sourced." "I look forward to keeping the market updated on our progress as we deliver sustainable, profitable growth." Further information: For more information on CSL's results and strategy updates announced today, the company will host a briefing at 10am AEST on 19 August, 2025 which can be accessed via CSL's investors website. Additional details about CSL's results are included in the company's 4E statement, investor presentation slides and webcast, all of which can be found on CSL's website Media ContactsBrett FoleyMobile: +61 461 464 708Email: Hamish WalshMobile: +61 422 424 338Email: View original content to download multimedia: SOURCE CSL Limited Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store